CN1314367A - 一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸 - Google Patents

一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸 Download PDF

Info

Publication number: CN1314367A
Authority: CN; China
Prior art keywords: polypeptide; polynucleotide; coupling factor; mitochondrial atp; sequence
Prior art date: 2000-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN 00114976

Other languages

English (en)

Chinese (zh)

Inventor

毛裕民

谢毅

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Shanghai Biowindow Gene Development Inc

Original Assignee

Shanghai Biowindow Gene Development Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-17

Filing date

2000-03-17

Publication date

2001-09-26

2000-03-17 Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc

2000-03-17 Priority to CN 00114976 priority Critical patent/CN1314367A/zh

2001-03-16 Priority to AU50243/01A priority patent/AU5024301A/en

2001-03-16 Priority to PCT/CN2001/000330 priority patent/WO2001079424A2/fr

2001-09-26 Publication of CN1314367A publication Critical patent/CN1314367A/zh

Status Pending legal-status Critical Current

Links

230000008878 coupling Effects 0.000 title claims abstract description 140
238000010168 coupling process Methods 0.000 title claims abstract description 140
238000005859 coupling reaction Methods 0.000 title claims abstract description 140
108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 117
108091033319 polynucleotide Proteins 0.000 title claims abstract description 114
239000002157 polynucleotide Substances 0.000 title claims abstract description 114
102000040430 polynucleotide Human genes 0.000 title claims abstract description 114
229920001184 polypeptide Polymers 0.000 title claims abstract description 110
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 109
210000003470 mitochondria Anatomy 0.000 title abstract description 4
238000000034 method Methods 0.000 claims abstract description 84
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 40
201000010099 disease Diseases 0.000 claims abstract description 33
239000005557 antagonist Substances 0.000 claims abstract description 18
230000000694 effects Effects 0.000 claims abstract description 11
206010061218 Inflammation Diseases 0.000 claims abstract description 8
230000004054 inflammatory process Effects 0.000 claims abstract description 8
208000026278 immune system disease Diseases 0.000 claims abstract description 7
201000011510 cancer Diseases 0.000 claims abstract description 6
208000031886 HIV Infections Diseases 0.000 claims abstract description 4
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 4
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 4
230000002438 mitochondrial effect Effects 0.000 claims description 138
239000000523 sample Substances 0.000 claims description 70
108090000623 proteins and genes Proteins 0.000 claims description 65
238000009396 hybridization Methods 0.000 claims description 37
239000002773 nucleotide Substances 0.000 claims description 31
125000003729 nucleotide group Chemical group 0.000 claims description 31
239000012634 fragment Substances 0.000 claims description 30
230000014509 gene expression Effects 0.000 claims description 29
150000007523 nucleic acids Chemical class 0.000 claims description 24
150000001875 compounds Chemical class 0.000 claims description 21
102000039446 nucleic acids Human genes 0.000 claims description 18
108020004707 nucleic acids Proteins 0.000 claims description 18
230000000295 complement effect Effects 0.000 claims description 15
239000013604 expression vector Substances 0.000 claims description 13
239000013598 vector Substances 0.000 claims description 12
239000013612 plasmid Substances 0.000 claims description 11
239000000556 agonist Substances 0.000 claims description 10
238000006243 chemical reaction Methods 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 8
239000003112 inhibitor Substances 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 6
230000003321 amplification Effects 0.000 claims description 6
238000003199 nucleic acid amplification method Methods 0.000 claims description 6
230000000692 anti-sense effect Effects 0.000 claims description 5
238000003745 diagnosis Methods 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 3
238000001727 in vivo Methods 0.000 claims description 3
238000002493 microarray Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000008485 antagonism Effects 0.000 claims description 2
238000013459 approach Methods 0.000 claims description 2
208000022602 disease susceptibility Diseases 0.000 claims description 2
238000004088 simulation Methods 0.000 claims description 2
239000003981 vehicle Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 6
230000008569 process Effects 0.000 abstract description 6
108091006112 ATPases Proteins 0.000 abstract description 5
102000057290 Adenosine Triphosphatases Human genes 0.000 abstract description 5
206010012559 Developmental delay Diseases 0.000 abstract description 4
238000012270 DNA recombination Methods 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 61
108020004414 DNA Proteins 0.000 description 44
150000001413 amino acids Chemical class 0.000 description 42
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
239000002299 complementary DNA Substances 0.000 description 34
238000005516 engineering process Methods 0.000 description 29
102000004169 proteins and genes Human genes 0.000 description 25
235000018102 proteins Nutrition 0.000 description 23
210000001519 tissue Anatomy 0.000 description 23
229940024606 amino acid Drugs 0.000 description 22
235000001014 amino acid Nutrition 0.000 description 22
108091032973 (ribonucleotides)n+m Proteins 0.000 description 20
239000000047 product Substances 0.000 description 20
108091028043 Nucleic acid sequence Proteins 0.000 description 18
230000008859 change Effects 0.000 description 16
108091034117 Oligonucleotide Proteins 0.000 description 14
238000003752 polymerase chain reaction Methods 0.000 description 14
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
230000006870 function Effects 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
238000001556 precipitation Methods 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
108020004999 messenger RNA Proteins 0.000 description 10
241000894006 Bacteria Species 0.000 description 9
239000000203 mixture Substances 0.000 description 9
238000000926 separation method Methods 0.000 description 9
238000012360 testing method Methods 0.000 description 9
238000005406 washing Methods 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
125000000539 amino acid group Chemical group 0.000 description 8
230000008034 disappearance Effects 0.000 description 8
239000012528 membrane Substances 0.000 description 8
238000012216 screening Methods 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000001228 spectrum Methods 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
108091026890 Coding region Proteins 0.000 description 7
108010043287 F(6) ATPase Proteins 0.000 description 7
206010028980 Neoplasm Diseases 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
102100027782 ATP synthase-coupling factor 6, mitochondrial Human genes 0.000 description 6
230000002159 abnormal effect Effects 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000008827 biological function Effects 0.000 description 6
230000008521 reorganization Effects 0.000 description 6
230000002759 chromosomal effect Effects 0.000 description 5
230000000875 corresponding effect Effects 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
238000010369 molecular cloning Methods 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
238000000018 DNA microarray Methods 0.000 description 4
206010058314 Dysplasia Diseases 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
238000000636 Northern blotting Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
210000003527 eukaryotic cell Anatomy 0.000 description 4
230000008175 fetal development Effects 0.000 description 4
230000001900 immune effect Effects 0.000 description 4
238000007901 in situ hybridization Methods 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
-1 liver Chemical compound 0.000 description 4
238000010839 reverse transcription Methods 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
206010027336 Menstruation delayed Diseases 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
108020005091 Replication Origin Proteins 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
210000000349 chromosome Anatomy 0.000 description 3
238000013016 damping Methods 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000001415 gene therapy Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
108060003552 hemocyanin Proteins 0.000 description 3
210000003917 human chromosome Anatomy 0.000 description 3
210000004754 hybrid cell Anatomy 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
230000008520 organization Effects 0.000 description 3
239000002953 phosphate buffered saline Substances 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
229960004249 sodium acetate Drugs 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
210000001541 thymus gland Anatomy 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 2
MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 2
MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 2
MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 2
MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000019838 Blood disease Diseases 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
108091033380 Coding strand Proteins 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
108010067770 Endopeptidase K Proteins 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
LVWVMRBMGDJZLM-UHFFFAOYSA-N Oligomycin D Natural products C1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 LVWVMRBMGDJZLM-UHFFFAOYSA-N 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
108091034057 RNA (poly(A)) Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
229930189591 Rutamycin Natural products 0.000 description 2
108091081021 Sense strand Proteins 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
239000000427 antigen Substances 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
229910052785 arsenic Inorganic materials 0.000 description 2
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 2
230000027455 binding Effects 0.000 description 2
239000012472 biological sample Substances 0.000 description 2
238000001574 biopsy Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
238000006555 catalytic reaction Methods 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
201000010989 colorectal carcinoma Diseases 0.000 description 2
230000007547 defect Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000001605 fetal effect Effects 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
208000014951 hematologic disease Diseases 0.000 description 2
208000018706 hematopoietic system disease Diseases 0.000 description 2
230000036571 hydration Effects 0.000 description 2
238000006703 hydration reaction Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000009413 insulation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
108010073472 leucyl-prolyl-proline Proteins 0.000 description 2
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000002502 liposome Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000002969 morbid Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229930191479 oligomycin Natural products 0.000 description 2
MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 2
230000010627 oxidative phosphorylation Effects 0.000 description 2
238000012856 packing Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
LVWVMRBMGDJZLM-WXPRFNGZSA-N rutamycin Chemical compound O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H](C2)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 LVWVMRBMGDJZLM-WXPRFNGZSA-N 0.000 description 2
229950004416 rutamycin Drugs 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
238000012882 sequential analysis Methods 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
230000003595 spectral effect Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
230000017105 transposition Effects 0.000 description 2
235000013311 vegetables Nutrition 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
238000001262 western blot Methods 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 1
UZGKAASZIMOAMU-UHFFFAOYSA-N 124177-85-1 Chemical compound NP(=O)=O UZGKAASZIMOAMU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
AFMZNQYNOSEBLP-YGOYTEALSA-N 5-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-prop-2-ynyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(N)=CN1[C@]1(CC#C)O[C@H](CO)[C@@H](O)C1 AFMZNQYNOSEBLP-YGOYTEALSA-N 0.000 description 1
FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
101710157526 ATP synthase subunit 5, mitochondrial Proteins 0.000 description 1
101710117604 ATP synthase subunit O, mitochondrial Proteins 0.000 description 1
102100021870 ATP synthase subunit O, mitochondrial Human genes 0.000 description 1
206010000234 Abortion spontaneous Diseases 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
OPEPUCYIGFEGSW-WDSKDSINSA-N Asn-Gly-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O OPEPUCYIGFEGSW-WDSKDSINSA-N 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
208000017897 Carcinoma of esophagus Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
206010056467 Cerebral dysgenesis Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010009269 Cleft palate Diseases 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
206010018325 Congenital glaucomas Diseases 0.000 description 1
206010010506 Congenital hydrocephalus Diseases 0.000 description 1
ABLQPNMKLMFDQU-BIIVOSGPSA-N Cys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CS)N)C(=O)O ABLQPNMKLMFDQU-BIIVOSGPSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
206010011882 Deafness congenital Diseases 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012565 Developmental glaucoma Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
206010013883 Dwarfism Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010014759 Endometrial neoplasm Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
201000008808 Fibrosarcoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
XGBVLRJLHUVCNK-DCAQKATOSA-N His-Val-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O XGBVLRJLHUVCNK-DCAQKATOSA-N 0.000 description 1
101000829958 Homo sapiens N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Proteins 0.000 description 1
SVZFKLBRCYCIIY-CYDGBPFRSA-N Ile-Pro-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SVZFKLBRCYCIIY-CYDGBPFRSA-N 0.000 description 1
NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
208000035478 Interatrial communication Diseases 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
DPURXCQCHSQPAN-AVGNSLFASA-N Leu-Pro-Pro Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DPURXCQCHSQPAN-AVGNSLFASA-N 0.000 description 1
XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 1
BRTVHXHCUSXYRI-CIUDSAMLSA-N Leu-Ser-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O BRTVHXHCUSXYRI-CIUDSAMLSA-N 0.000 description 1
VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010024612 Lipoma Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
KJIXWRWPOCKYLD-IHRRRGAJSA-N Lys-Lys-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)N KJIXWRWPOCKYLD-IHRRRGAJSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
ZIIMORLEZLVRIP-SRVKXCTJSA-N Met-Leu-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZIIMORLEZLVRIP-SRVKXCTJSA-N 0.000 description 1
PHKBGZKVOJCIMZ-SRVKXCTJSA-N Met-Pro-Arg Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PHKBGZKVOJCIMZ-SRVKXCTJSA-N 0.000 description 1
CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
102100023315 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase Human genes 0.000 description 1
125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 1
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000008846 Neurocytoma Diseases 0.000 description 1
201000004404 Neurofibroma Diseases 0.000 description 1
206010030155 Oesophageal carcinoma Diseases 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
SEPNOAFMZLLCEW-UBHSHLNASA-N Phe-Ala-Val Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O SEPNOAFMZLLCEW-UBHSHLNASA-N 0.000 description 1
AGYXCMYVTBYGCT-ULQDDVLXSA-N Phe-Arg-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O AGYXCMYVTBYGCT-ULQDDVLXSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
DYMPSOABVJIFBS-IHRRRGAJSA-N Pro-Phe-Cys Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CS)C(=O)O DYMPSOABVJIFBS-IHRRRGAJSA-N 0.000 description 1
CGSOWZUPLOKYOR-AVGNSLFASA-N Pro-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 CGSOWZUPLOKYOR-AVGNSLFASA-N 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
BFDMCHRDSYTOLE-UHFFFAOYSA-N SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 Chemical compound SC#N.NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 BFDMCHRDSYTOLE-UHFFFAOYSA-N 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MOVJSUIKUNCVMG-ZLUOBGJFSA-N Ser-Cys-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)O)N)O MOVJSUIKUNCVMG-ZLUOBGJFSA-N 0.000 description 1
VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
QUGRFWPMPVIAPW-IHRRRGAJSA-N Ser-Pro-Phe Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QUGRFWPMPVIAPW-IHRRRGAJSA-N 0.000 description 1
NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108700007696 Tetrahydrofolate Dehydrogenase Proteins 0.000 description 1
PKXHGEXFMIZSER-QTKMDUPCSA-N Thr-Arg-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O PKXHGEXFMIZSER-QTKMDUPCSA-N 0.000 description 1
VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
208000000728 Thymus Neoplasms Diseases 0.000 description 1
208000024770 Thyroid neoplasm Diseases 0.000 description 1
208000024212 Tracheal Neoplasms Diseases 0.000 description 1
108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
239000006035 Tryptophane Substances 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
239000005030 aluminium foil Substances 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
230000002788 anti-peptide Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000013914 atrial heart septal defect Diseases 0.000 description 1
206010003664 atrial septal defect Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000011953 bioanalysis Methods 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000012295 chemical reaction liquid Substances 0.000 description 1
208000023652 chronic gastritis Diseases 0.000 description 1
201000009151 chronic rhinitis Diseases 0.000 description 1
230000004087 circulation Effects 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000013399 edible fruits Nutrition 0.000 description 1
201000003914 endometrial carcinoma Diseases 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
201000005619 esophageal carcinoma Diseases 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
230000004992 fission Effects 0.000 description 1
239000005357 flat glass Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
201000008361 ganglioneuroma Diseases 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
229960002989 glutamic acid Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000012010 growth Effects 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
125000000487 histidyl group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
208000003906 hydrocephalus Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
231100000608 immunotoxin Toxicity 0.000 description 1
229940051026 immunotoxin Drugs 0.000 description 1
230000008676 import Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
108010044056 leucyl-phenylalanine Proteins 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
206010024627 liposarcoma Diseases 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000010841 mRNA extraction Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
230000013011 mating Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000008558 metabolic pathway by substance Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000031864 metaphase Effects 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
208000015994 miscarriage Diseases 0.000 description 1
108091064355 mitochondrial RNA Proteins 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
201000011216 nasopharynx carcinoma Diseases 0.000 description 1
239000005445 natural material Substances 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
201000010193 neural tube defect Diseases 0.000 description 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
210000002220 organoid Anatomy 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000003123 plant toxin Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000012805 post-processing Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000000197 pyrolysis Methods 0.000 description 1
238000012797 qualification Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000003156 radioimmunoprecipitation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
239000002342 ribonucleoside Substances 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000007789 sealing Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
108010048818 seryl-histidine Proteins 0.000 description 1
108010026333 seryl-proline Proteins 0.000 description 1
230000036301 sexual development Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
241000894007 species Species 0.000 description 1
238000010183 spectrum analysis Methods 0.000 description 1
208000000995 spontaneous abortion Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
201000000498 stomach carcinoma Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
208000013076 thyroid tumor Diseases 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
208000024363 trachea neoplasm Diseases 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003151 transfection method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
208000012991 uterine carcinoma Diseases 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000009736 wetting Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CN 00114976 2000-03-17 2000-03-17 一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸 Pending CN1314367A (zh)

Priority Applications (3)

Application Number	Priority Date	Filing Date	Title
CN 00114976 CN1314367A (zh)	2000-03-17	2000-03-17	一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸
AU50243/01A AU5024301A (en)	2000-03-17	2001-03-16	A novel polypeptide, a human coupling atpase mitochondrial 6-10 factor and the polynucleotide encoding the polypeptide
PCT/CN2001/000330 WO2001079424A2 (fr)	2000-03-17	2001-03-16	Nouveau polypeptide, facteur humaine de couplage d'atpase mitochondriale 6-10, et polynucleotide codant pour ce polypeptide

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN 00114976 CN1314367A (zh)	2000-03-17	2000-03-17	一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸

Publications (1)

Publication Number	Publication Date
CN1314367A true CN1314367A (zh)	2001-09-26

Family

ID=4584447

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN 00114976 Pending CN1314367A (zh)	2000-03-17	2000-03-17	一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸

Country Status (3)

Country	Link
CN (1)	CN1314367A (fr)
AU (1)	AU5024301A (fr)
WO (1)	WO2001079424A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11426046B2 (en)	2018-12-03	2022-08-30	Sharkninja Operating Llc	Optical indicium for communicating information to autonomous devices

2000
- 2000-03-17 CN CN 00114976 patent/CN1314367A/zh active Pending
2001
- 2001-03-16 WO PCT/CN2001/000330 patent/WO2001079424A2/fr not_active Ceased
- 2001-03-16 AU AU50243/01A patent/AU5024301A/en not_active Abandoned

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11426046B2 (en)	2018-12-03	2022-08-30	Sharkninja Operating Llc	Optical indicium for communicating information to autonomous devices

Also Published As

Publication number	Publication date
WO2001079424A3 (fr)	2002-03-28
WO2001079424A2 (fr)	2001-10-25
AU5024301A (en)	2001-10-30

Publication	Publication Date	Title
CN1314359A (zh)	2001-09-26	一种新的多肽——肿瘤抑制因子63和编码这种多肽的多核苷酸
CN1314486A (zh)	2001-09-26	一种新的多肽——人组氨酰－tRNA合成酶85和编码这种多肽的多核苷酸
CN1314476A (zh)	2001-09-26	一种新的多肽——人磷脂酰肌醇3(PtdIns 3)－激酶36和编码这种多肽的多核苷酸
CN1333245A (zh)	2002-01-30	一种新的多肽——人核孔蛋白p54－16.61和编码这种多肽的多核苷酸
CN1314367A (zh)	2001-09-26	一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸
CN1333264A (zh)	2002-01-30	一种新的多肽——人细胞增殖相关蛋白53.68和编码这种多肽的多核苷酸
CN1314381A (zh)	2001-09-26	一种新的多肽——人运动性共济失调－毛细管扩张atm蛋白20和编码这种多肽的多核苷税
CN1314482A (zh)	2001-09-26	一种新的多肽——人磷脂酰肌醇3(PtdIns 3)－激酶9和编码这种多肽的多核苷酸
CN1364881A (zh)	2002-08-21	一种新的多肽——人核糖核酸聚合酶ii7亚基26.73和编码这种多肽的多核苷酸
CN1314480A (zh)	2001-09-26	一种新的多肽——人磷脂酰肌醇3激酶14和编码这种多肽的多核苷酸
CN1311204A (zh)	2001-09-05	一种新的多肽——人腺苷三磷酸30和编码这种多肽的多核苷酸
CN1313314A (zh)	2001-09-19	一种新的多肽——人信号识别因子12和编码这种多肽的多核苷酸
CN1312381A (zh)	2001-09-12	一种新的多肽——人环腺苷酸磷酸二脂酶13和编码这种多肽的多核苷酸
CN1315396A (zh)	2001-10-03	一种新的多肽——人线粒体atp酶耦合因子6－14和编码这种多肽的多核苷酸
CN1313322A (zh)	2001-09-19	一种新的多肽——人视网膜瘤结合蛋白9和编码这种多肽的多核苷酸
CN1312267A (zh)	2001-09-12	一种新的多肽——人nf－e2相关因子14和编码这种多肽的多核苷酸
CN1314395A (zh)	2001-09-26	一种新的多肽——人前列腺特异的膜抗体蛋白9和编码这种多肽的多核苷酸
CN1352164A (zh)	2002-06-05	一种新的多肽——人外被体蛋白(copa)15.73和编码这种多肽的多核苷酸
CN1331334A (zh)	2002-01-16	一种新的多肽——rna解螺旋酶a21.01和编码这种多肽的多核苷酸
CN1358754A (zh)	2002-07-17	一种新的多肽——人dna复制因子c亚基8.91和编码这种多肽的多核苷酸
CN1315372A (zh)	2001-10-03	一种新的多肽——人肿瘤相关核蛋白12和编码这种多肽的多核苷酸
CN1361137A (zh)	2002-07-31	一种新的多肽——人视网膜瘤结合蛋白10.45和编码这种多肽的多核苷酸
CN1320625A (zh)	2001-11-07	一种新的多肽——人DNA复制因子C(A1)37Kd亚基49和编码这种多肽的多核苷酸
CN1314409A (zh)	2001-09-26	一种新的多肽——人共济失调－毛细血管扩张症突变蛋白11和编码这种多肽的多核苷酸
CN1311252A (zh)	2001-09-05	一种新的多肽——人反转录相关蛋白9和编码这种多肽的多核苷酸

Legal Events

Date	Code	Title
2001-09-26	C06	Publication
2001-09-26	PB01	Publication
2003-12-17	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2003-12-17	WD01	Invention patent application deemed withdrawn after publication

CN1314367A - 一种新的多肽——人线粒体ATPase耦合因子6－10和编码这种多肽的多核苷酸 - Google Patents

Info

Links

Images

Classifications

Landscapes

Priority Applications (3)

Applications Claiming Priority (1)

Publications (1)

Family

ID=4584447

Family Applications (1)

Country Status (3)

Cited By (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events